In 2025, YRPG’s international revenue rose over fourfold year‑on‑year, expanding exports to 100+ products in 40+ markets.
The group earned the Seven‑Star EFQM certification, becoming the first Chinese pharma firm recognized under the European Excellence framework.
YRPG secured EMA, FDA, PMDA approvals, passed Uganda GMP inspection, and added WHO‑GACP certified cultivation bases in Fujian and Inner Mongolia.
Plans include a new Pangdahai cultivation base in Laos and expanding technical services worldwide, marking a 2026 global expansion phase.